Oxidative stress and response in relation to coronary artery disease in type 1 diabetes

Tina Costacou, Rhobert W Evans, Gerald L Schafer, Trevor J Orchard, Tina Costacou, Rhobert W Evans, Gerald L Schafer, Trevor J Orchard

Abstract

Objective: Although oxidative stress (OxS) is thought to contribute to atherosclerosis and coronary artery disease (CAD), little is known about the variability in an individual's ability to respond to OxS. Therefore, we assessed potential indices of response to OxS and evaluated whether they modify the association between OxS and CAD.

Research design and methods: We evaluated plasma α- and γ-tocopherol per unit cholesterol (potential response markers); urinary 15-isoprostane F2t per milligram creatinine (isoprostane [IsoP], a potential stress marker); and the α-tocopherol-to-IsoP ratio (as a measure of response to stress), measured three times during 20 years of follow-up, in relation to CAD incidence in a cohort with childhood-onset type 1 diabetes (n = 658; mean age at baseline, 28 years; duration of diabetes, 19 years). Participants with three samples (blood and either 24-h or overnight urine) available before the onset of CAD or the end of follow-up (n = 356) were selected for study.

Results: In multivariable mixed models, α-tocopherol over time was inversely associated with CAD (β = -0.27; P = 0.02), whereas a direct association was observed for IsoP (β = 0.0008; P = 0.06). Moreover, the α-tocopherol-to-IsoP ratio was strongly and inversely related to CAD incidence (β = -0.72; P = 0.003), whereas in a separate model including α-tocopherol and IsoP, both biomarkers maintained statistical significance. No association was observed for γ-tocopherol (β = -0.22; P = 0.54).

Conclusions: These data suggest that a greater potential capability (α-tocopherol) to respond to OxS (urinary IsoP) relates to CAD incidence.

Figures

Figure 1
Figure 1
α-Tocopherol and urinary IsoP trajectories (A) and α-tocopherol-to-urinary IsoP ratio trajectories (B) (adjusted for duration of diabetes, race, sex, BMI, having ever smoked, HbA1c, hypertension, HDL and non-HDL cholesterol, albumin excretion rate (log), estimated glomerular filtration rate, and white blood cell count) before a CAD event or the end of follow-up.

References

    1. McCall MR, Frei B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 1999;26:1034–1053
    1. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1–9
    1. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505–513
    1. Institute of Medicine, Food and Nutrition Board Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC, National Academy Press, 2000
    1. Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol 2008;101(10A):75D–86D
    1. Costacou T, Zgibor JC, Evans RW, Tyurina YY, Kagan VE, Orchard TJ. Antioxidants and coronary artery disease among individuals with type 1 diabetes: Findings from the Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 2006;20:387–394
    1. The hypertension detection and follow-up program: hypertension detection and follow-up program cooperative group. Prev Med 1976;5:207–215
    1. Warnick GR, Albers JJ. Heparin—Mn2+ quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978;24:900–904
    1. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470–475
    1. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476–482
    1. Ellis D, Buffone GJ. New approach to evaluation of proteinuric states. Clin Chem 1977;23:666–670
    1. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612
    1. Driskell WJ, Neese JW, Bryant CC, Bashor MM. Measurement of vitamin A and vitamin E in human serum by high-performance liquid chromatography. J Chromatogr A 1982;231:439–444
    1. Miller KW, Lorr NA, Yang CS. Simultaneous determination of plasma retinol, alpha-tocopherol, lycopene, alpha-carotene, and beta-carotene by high-performance liquid chromatography. Anal Biochem 1984;138:340–345
    1. Evans RW, Shaten BJ, Day BW, Kuller LH. Prospective association between lipid soluble antioxidants and coronary heart disease in men. The Multiple Risk Factor Intervention Trial. Am J Epidemiol 1998;147:180–186
    1. Jordan P, Brubacher D, Moser U, Stähelin HB, Gey KF. Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression. Clin Chem 1995;41:924–927
    1. Thomas SR, Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radic Biol Med 2000;28:1795–1805
    1. Pizer SM. Numerical Computing and Mathematical Analysis. Pizer SM, Ed. Chicago, IL, Science Research Associates, Inc., 1975
    1. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017–2023
    1. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–786
    1. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213–1218
    1. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997;349:1715–1720
    1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999;354:447–455
    1. Levy AP, Gerstein HC, Miller-Lotan R, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004;27:2767.
    1. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008;28:341–347
    1. Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis 2010;211:25–27
    1. Costacou T, Orchard TJ. Adiponectin: good, bad, or just plain ugly? Kidney Int 2008;74:549–551
    1. Traber MG, Arai H. Molecular mechanisms of vitamin E transport. Annu Rev Nutr 1999;19:343–355
    1. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360–366
    1. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ., 2nd A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990;87:9383–9387
    1. Helmersson J, Basu S. F(2)-isoprostane and prostaglandin F(2 alpha)metabolite excretion rate and day to day variation in healthy humans. Prostaglandins Leukot Essent Fatty Acids 2001;65:99–102
    1. Keaney JF, Jr, Larson MG, Vasan RS, et al. Framingham Study Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434–439
    1. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004;109:843–848
    1. Polidori MC, Praticó D, Parente B, et al. Elevated lipid peroxidation biomarkers and low antioxidant status in atherosclerotic patients with increased carotid or iliofemoral intima media thickness. J Investig Med 2007;55:163–167
    1. Shishehbor MH, Zhang R, Medina H, et al. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 2006;41:1678–1683
    1. Basarici I, Altekin RE, Demir I, Yilmaz H. Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angiographic measures of atherosclerosis. Coron Artery Dis 2007;18:615–620
    1. Roest M, Voorbij HA, Van der Schouw YT, Peeters PH, Teerlink T, Scheffer PG. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J Clin Lipidol 2008;2:298–303
    1. Flores L, Rodela S, Abian J, Clària J, Esmatjes E. F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism 2004;53:1118–1120
    1. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:131–139
    1. Nojiri S, Daida H, Mokuno H, et al. Association of serum antioxidant capacity with coronary artery disease in middle-aged men. Jpn Heart J 2001;42:677–690
    1. Valabhji J, McColl AJ, Richmond W, Schachter M, Rubens MB, Elkeles RS. Total antioxidant status and coronary artery calcification in type 1 diabetes. Diabetes Care 2001;24:1608–1613
    1. Woo J, Leung SS, Lam CW, Ho SC, Lam TH, Janus ED. Plasma total antioxidant capacity in an adult Hong Kong Chinese population. Clin Biochem 1997;30:553–557

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit